Effects of latanoprost and betaxolol on cardiovascular and respiratory status of newly diagnosed glaucoma patients

Ophthalmologica

Volumn 220, Issue 5, 2006, Pages 332-337

  Erkin, Esin F ^a,b   Çelik, Pinar ^a   Kayikçioǧlu, Özcan ^a   Deveci, Hülya Mutlu ^a   Şakar, Ayşin ^a  

^a CELAL BAYAR UNIVERSITY   (Turkey)

^b NONE   (Turkey)

Author keywords

Betaxolol; Cardiovascular effects; Glaucoma; Latanoprost; Respiratory effects

Indexed keywords

BETAXOLOL; LATANOPROST;

ARTICLE; CARDIOVASCULAR EFFECT; CLINICAL ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DIASTOLIC BLOOD PRESSURE; DRUG EFFECT; FEMALE; GLAUCOMA; HUMAN; INTRAOCULAR PRESSURE; MALE; PULSE RATE; RANDOMIZED CONTROLLED TRIAL; RESPIRATORY FUNCTION; SPIROMETRY; SYSTOLIC BLOOD PRESSURE; TREATMENT OUTCOME;

ADULT; AGED; AGED, 80 AND OVER; ANTIHYPERTENSIVE AGENTS; BETAXOLOL; BLOOD PRESSURE; CARDIOVASCULAR SYSTEM; FEMALE; GLAUCOMA, OPEN-ANGLE; HEART RATE; HUMANS; INTRAOCULAR PRESSURE; MALE; MIDDLE AGED; PROSPECTIVE STUDIES; PROSTAGLANDINS F, SYNTHETIC; RESPIRATION; SPIROMETRY;

EID: 33748463034     PISSN: 00303755     EISSN: None     Source Type: Journal    
DOI: 10.1159/000094625     Document Type: Article

References (24)

1. Klein BE, Klein R, Sponsel W, Franke T, Cantor LB, Martone J, Menage MJI: Prevalence of glaucoma: The Beaver Dam Eye Study. Ophthalmology 1992;99:1499-1504.
2. Diggory P, Cassels-Brown A, Vail A, Abbey LM, Hillman JS: Avoiding unsuspected respiratory side-effects of topical timolol with cardioselective or sympathomimetic agents. Lancet 1995;345:1604-1606.
3. Diggory P, Cassels-Brown A, Vail A, Hillman JS: Randomised, controlled trial of spirometric changes in elderly people receiving timolol or betaxolol as initial treatment for glaucoma. Br J Ophthalmol 1998;82:146-149.
4. Hedner J, Everts B, Moller CS: Latanoprost and respiratory function in asthmatic patients: Randomized, double-masked, placebo controlled crossover evaluation. Arch Ophthalmol 1999;117:1305-1309.
5. Waldock A, Snape J, Graham CM: Effects of glaucoma medications on the cardiorespiratory and intraocular pressure status of newly diagnosed glaucoma patients. Br J Ophthalmol 2000;84:710-713.
6. Hedner J, Svedmyr N, Lunde H, Mandahl A: The lack of respiratory effects of ocular hypotensive drug latanoprost in patients with moderate-steroid treated asthma. Surv Ophthalmol 1997;41(suppl 2):S111-S115.
7. Stewart WC, Garrison PM: Beta-blocker-induced complications and the patients with glaucoma. Newer treatments to help reduce systemic adverse events. Arch Intern Med 1998;9:221-226.
8. Banerjee DK, Lee GS, Malik SK, Daly S: Underdiagnosis of asthma in the elderly. Br J Dis Chest 1987;81:23-29.
9. Connolly MJ, Crowley JJ, Neilson CP, Vesatl RE: Reduced subjective awareness of bronchoconstriction provoked by methacholine in elderly asthmatic and normal subjects as measured on a simple awareness scale. Thorax 1992;47:410-413.
10. Schoene RB, Abuan RN, Ward RL, Beasley H: Effects of topical betaxolol, timolol and placebo on pulmonary function in asthmatic bronchitis. Am J Ophthalmol 1984;97:86-92.
11. Brooks AM, Gillies WE: Ocular beta-blockers in glaucoma management. Clinical pharmacological aspects. Drugs Aging 1992;2:208-221.
12. Diggory P, Heyworth P, Chau G, McKenzie S, Sharma A, Luke I: Improved lung function tests on changing from topical timolol. Non-selective beta-blockade impairs the lung function tests in elderly patients. Eye 1993;7:661-667.
13. Linden C, Alm A: Prostaglandin analogues in the treatment of glaucoma. Drugs Aging 1999;14:387-398.
14. Novack GD, O'Donnell MJ, Molloy W: New glaucoma medications in the geriatric population: Efficacy and safety. J Am Geriatr Soc 2002;50:956-962.
15. Perrry CM, McGavin JK, Culy CR, Ibbotson T: Latanoprost: An update of its use in glaucoma and ocular hypertension. Drugs Aging 2003;20:597-630.
16. Grippi MA, Metzger LF, Sacks AV, Fishman AP: Pulmonary function testing; in Fishman AP (ed): Fishman's Pulmonary Diseases and Disorders. New York, McGraw Hill, 1998, pp 533-574.
17. Avorn J, Glynn R, Gurwitz JH: Pulmonary effects of beta blockers. J Glaucoma 1993;2:158-165.
18. Yamada Y, Takayanagi R, Tsuchiya K, Ito K, Ohtani H, Sawada Y, Iga T: Assessment of systemic adverse reactions induced by ophthalmic beta-adrenergic receptor antagonists. J Ocul Pharmacol Ther 2001;17:235-248.
19. Alm A: Prostaglandin derivatives as ocular hypotensive agents. Prog Retin Eye Res 1998;17:291-312.
20. Sjöquist B, Stjernschantz J: Ocular and systemic pharmacokinetics of latanoprost in humans. Surv Ophthalmol 2002;47(suppl 1):S6-S12.
21. 2α analogue. Adv Prostaglandin Thromboxane Leukot Res 1995;23:513-518.
22. 2 and related prostaglandins in airways. Fundam Clin Pharmacol 1997;11:2-18.
23. 2α. Naunyn Schmiedebergs Arch Pharmacol 1990;341:439-443.
24. Stjernschantz J: Prostaglandins as ocular hypotensive agents: Development of an analogue for glaucoma treatment. Adv Prostaglandin Thromboxane Leukot Res 1995;23:63-68.